PepGen reports favorable safety profile for PGN-EDO51 in Phase 2 DMD trial at WMS Congress

PepGen Inc.

CONNECT1-EDO51 safety data as of Oct 3: no serious adverse events; all treatment-related AEs mild and resolved.
One hypomagnesemia case resolved with oral supplementation; no discontinuations, dose interruptions or reductions.
Presenting short oral and five posters on PGN-EDO51 (DMD) and PGN-EDODM1 (DM1) at WMS Congress in Prague Oct 8-12.
Nonclinical data for both programs and FREEDOM-DM1 trial design also featured in poster sessions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.